PACAP is a pathogen-inducible resident antimicrobial neuropeptide affording rapid and contextual molecular host defense of the brain by Lee, Ernest Y. et al.
PACAP is a pathogen-inducible resident antimicrobial
neuropeptide affording rapid and contextual molecular
host defense of the brain
Ernest Y. Leea,b, Liana C. Chanc,d,e, Huiyuan Wangc,d, Juelline Lienga, Mandy Hunga, Yashes Srinivasana,
Jennifer Wanga, James A. Waschekf, Andrew L. Fergusong, Kuo-Fen Leeh, Nannette Y. Yountc,d,
Michael R. Yeamand,e,i,1,2, and Gerard C. L. Wonga,j,k,1,2
aDepartment of Bioengineering, University of California, Los Angeles, CA 90095; bUCLA-Caltech Medical Scientist Training Program, David Geffen School of
Medicine at UCLA, Los Angeles, CA 90095; cLundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90509; dDivision of
Molecular Medicine, Los Angeles County, Harbor-UCLA Medical Center, Torrance, CA 90509; eDivision of Infectious Diseases, Los Angeles County, Harbor-
UCLA Medical Center, Torrance, CA 90509; fSemel Institute for Neuroscience and Human Behavior, Intellectual Development and Disabilities Research
Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; gPritzker School of Molecular Engineering, University of Chicago,
Chicago, IL 60637; hPeptide Biology Laboratories, Salk Institute for Biological Studies, La Jolla, CA 92037; iDepartment of Medicine, David Geffen School of
Medicine, University of California, Los Angeles, CA 90095; jDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095;
and kCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095
Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved October 12, 2020 (received for review August 4, 2020)
Defense of the central nervous system (CNS) against infection must
be accomplished without generation of potentially injurious im-
mune cell-mediated or off-target inflammation which could impair
key functions. As the CNS is an immune-privileged compartment,
inducible innate defense mechanisms endogenous to the CNS likely
play an essential role in this regard. Pituitary adenylate cyclase-
activating polypeptide (PACAP) is a neuropeptide known to regulate
neurodevelopment, emotion, and certain stress responses. While
PACAP is known to interact with the immune system, its significance
in direct defense of brain or other tissues is not established. Here,
we show that our machine-learning classifier can screen for immune
activity in neuropeptides, and correctly identified PACAP as an anti-
microbial neuropeptide in agreement with previous experimental
work. Furthermore, synchrotron X-ray scattering, antimicrobial as-
says, and mechanistic fingerprinting provided precise insights into
how PACAP exerts antimicrobial activities vs. pathogens via multiple
and synergistic mechanisms, including dysregulation of membrane
integrity and energetics and activation of cell death pathways. Im-
portantly, resident PACAP is selectively induced up to 50-fold in the
brain in mouse models of Staphylococcus aureus or Candida albicans
infection in vivo, without inducing immune cell infiltration. We show
differential PACAP induction even in various tissues outside the CNS,
and how these observed patterns of induction are consistent with
the antimicrobial efficacy of PACAP measured in conditions simulat-
ing specific physiologic contexts of those tissues. Phylogenetic anal-
ysis of PACAP revealed close conservation of predicted antimicrobial
properties spanning primitive invertebrates to modern mammals.
Together, these findings substantiate our hypothesis that PACAP is
an ancient neuro-endocrine-immune effector that defends the CNS
against infection while minimizing potentially injurious neuroin-
flammation.
neuropeptides | innate immunity | antimicrobial peptides |
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Neuropeptides enable interneuronal communication and sig-naling (1), mediating diverse functions ranging from endo-
crine stimulation and homeostatic regulation to immune signaling,
pain modulation, and circadian rhythm maintenance. At present,
over 100 neuropeptides are known in mammals (2). These pep-
tides originate from neurons in the central, enteric, or peripheral
nervous systems and within immune organs (3). Canonically,
neuropeptides exert their biological function by binding to a
cognate receptor (usually a G-coupled protein receptor [GPCR]),
triggering a signal transduction pathway that leads to a functional
change in the target cell (1). Neuropeptides are typically consid-
ered neurotransmitters or neurohormones, but recent work has
illuminated their potential roles in modulating immune responses
and neuroinflammation (4–8).
Human innate and adaptive immunity have evolved via two
parallel and complementary paradigms in host defense against
microbial invasion: molecular and cellular. Molecular defense
mediators are secreted or activated rapidly and locally to directly
inhibit pathogens. Prototypic examples include host-defense pep-
tides (HDPs), the acute-phase reactants, and the complement
cascade. Cellular defense involves infiltration of professional im-
mune phagocytes (neutrophils and macrophages) and lymphocytes
into infected tissues. Cellular infiltration into the central nervous
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system (CNS) is a double-edged sword, given its anatomically
confined space and physiologically delicate context. On one hand
cellular defense may be necessary to control or clear certain
pathogens. On the other hand, neutrophils and other phagocytes
can cause counterproductive damage to tissue parenchyma due to
production and release of reactive oxygen species and other cy-
totoxic constituents from phagolysosomes. Thus, molecular de-
fenses that are rapidly deployable in immediate settings of
infection to obviate the need for infiltration of potentially harmful
immune cells would be of special relevance in context of the CNS.
To explore putative molecular host-defense mediators within
the CNS that may have both neuro- and immunomodulatory
properties, we used a support vector machine (SVM) trained on
HDPs (9, 10) to identify neuropeptides with potential host de-
fense capabilities. Among the human neuropeptides identified as
potential HDPs for molecular host defense of the CNS is pitui-
tary adenylate cyclase-activating polypeptide (PACAP). PACAP
is a member of the vasoactive intestinal peptide (VIP)/PACAP/
secretin family (11) that regulates neurodevelopment (12), me-
tabolism, emotion, mood, and stress responses via GPCRs (13).
PACAP is known to interact with the immune system (14, 15)
and modulate T helper type 1 (TH1)/TH2 cytokine production
(3). Important previous work on structure activity relationships
(SAR) of PACAP have also shown that it possess antimicrobial
activity in vitro against a range of organisms (16–18), as well as
anti-cancer activity against tumor cell lines. (Interestingly, our
use of an SVM classifier that can scan different fragments of the
same peptide allows us to identify antimicrobial activity in pre-
viously identified metabolites of PACAP as well* (19)). How-
ever, host defense functions, contextual bioactivity, or pathogen-
specific inducibility of PACAP or other neuropeptides regarding
antimicrobial activity in vivo are not known. More specifically,
the role of PACAP in the larger context of innate immunity and
its in vivo relevance to antimicrobial defense of the CNS and in
other tissues remains unclear, given that antimicrobial activity is
strongly dependent on biochemical and physiological context
(20, 21, 22). Here, we examine PACAP inducibility in response
to infection in the CNS and other tissues, and whether PACAP
exerts antimicrobial activity against relevant organisms in the
specific biochemical context relevant to those tissues. Bio-
informatic and structural analyses showed PACAP to possess
almost identical structural similarity to human cathelicidin LL-
37, despite having overall low sequence similarity to other known
HDPs. Synchrotron X-ray scattering revealed that PACAP can
induce negative Gaussian curvature (NGC) in microbial mem-
branes, a general requirement for membrane-permeating anti-
microbial processes such as pore formation, blebbing, and other
membrane-perturbing events (23–25). Moreover, extending from
prior work (18), antimicrobial assays and mechanistic finger-
printing analyses showed that PACAP exerts potent antimicro-
bial mechanisms against drug-resistant bacteria and fungi via
multiple synergistic pathways, including permeabilization, dis-
ruption of cellular energetics, and activation of regulated cell
death pathways. In mouse models of bacterial or fungal infec-
tion, we demonstrated that PACAP is strongly induced up to
50-fold in brain, spleen, or kidney. Further, in media simulating
these tissue contexts, PACAP exerted robust microbiostatic and
microbicidal efficacy. Taken together, these findings imply that
PACAP is an infection-inducible, tissue-specific host-defense
effector that affords rapid and contextual antimicrobial host
defense in the CNS and periphery. Beyond immediate contri-
butions to better understanding of antimicrobial defense, the
present discoveries reveal specific intersections of neurological
and immunological systems and establish insights into anti-
infective strategies that preserve critical functions of the CNS.
Results
Machine Learning Predicts PACAP to Be Strongly Antimicrobial. We
collated human neuropeptide sequences from the database Neu-
roPep (2) and screened them for predicted membrane-permeating
activity using the MAPT (26). The distance-to-hyperplane (σ) of
each sequence was plotted vs. the homology of each sequence to
known ɑ-helical antimicrobial peptides (minHomologyAMP) and
superimposed on a sequence atlas generated from a Monte Carlo
search of the undiscovered sequence space spanning various mu-
tational distances (Fig. 1A). Large, positive values of σ indicate a
high probability of antimicrobial activity, while negative values of σ
indicate a low probability of antimicrobial activity. To visualize the
distribution of sequences based on their antimicrobial potential,
histograms of σ and minHomologyAMP were plotted (SI Appen-
dix, Fig. S1). The majority of sequences returned low σ scores,
consistent with their low sequence homology to known AMPs.
However, a small sequence set (∼10 sequences) received high scores
with σ > 0.8. Interestingly, among these the human PACAP isoform
1-38 was the top-scoring neuropeptide sequence (σ = 2.56, min-
HomologyAMP = 1.31) (Fig. 1A, purple). In comparison, the pro-
totypic ɑ-helical human AMP LL37 received a score of σ = 2.00
(minHomologyAMP = 0) (Fig. 1A, green). Physicochemical and
helical wheel analysis of the PACAP sequence revealed a striking
similarity to the human cathelicidin LL37, an innate immune
peptide with a broad range of host-defense functions (27, 28). Like
LL37, PACAP is cationic and facially amphipathic, with a segre-
gation of charged and hydrophobic residues (Fig. 1 B–D). These
peptides are also similar in size (PACAP, 38; LL-37, 37) and the
overall charge of PACAP is higher than LL37 at pH 7.4 (QPA-
CAP = +9.03 vs. QLL37 = +6.00). The size of the hydrophobic face
of LL37 is larger than PACAP (θLL37 ∼ 120° vs. θPACAP ∼ 90°) and
have hydrophobic moments of 0.36 and 0.09, respectively (Fig. 1 C
and D). Interestingly, PACAP and LL37 contain almost identical
proportions of K/K+R and mean hydrophobicity, and both fall
close to the saddle-splay selection rule for all known ɑ-helical
AMPs (9, 10) (Fig. 1E). As a result, PACAP is predicted to per-
turb microbial membranes similar to known AMPs, suggesting
that early selective forces may have favored multifunctional neu-
ropeptides with host-defense properties.
Despite low primary sequence identity, PACAP and LL37
exhibited high physicochemical similarities. A three-dimensional
structural alignment of PACAP and LL37 revealed a strikingly
strong structural homology (rmsd = 1.184 Å; Fig. 1F). In con-
trast, a sequence alignment of PACAP and LL37 showed es-
sentially zero sequence similarity or homology (Fig. 1G), implying
these peptides likely evolved independently. The cathelicidin and
defensin families of HDPs are known to be heterogeneous and
undergo rapid evolution, with substantial variation in both primary
sequence and physicochemical characteristics between species
(29–31). To study whether PACAP also exhibited such phyloge-
netic behavior, we conducted multiple sequence alignments of
PACAP across 11 organisms spanning 700 My of evolution
(SI Appendix, Fig. S2). As compared with the oldest organism,
Hydra, the human PACAP sequence shares 92% identity and
97% conservation; these correlates were identical to those of
murine PACAP. Furthermore, there is marked conservation
of the entire sequence across evolution, with the highest de-
gree of convergence in the N-terminal receptor-binding re-
gion and relatively greater diversity in the C-terminal eight
amino acid residues (SI Appendix, Fig. S2). Phylogenetic
analyses of PACAP sequences indicated they cluster into two
clades, with one representing the PACAP sequences in higher
vertebrates that exhibit arginine-to-lysine substitutions in
positions 32 and 36 (SI Appendix, Fig. S3).
*We have run the SVM classifier on the PACAP metabolite identified here and found it to
be antimicrobial but with a different score than the parent PACAP peptide, which is
consistent with the findings of the authors.
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Machine-learning screens of the 11 PACAP homologs pre-
dicted that all of the sequences would be antimicrobial, and that
differences in primary amino acid sequences across species do
not appreciably change this underlying property (SI Appendix,
Fig. S2). In light of this observation, we set out to systematically
map the membrane activity fitness landscape of PACAP. Using
the MAPT, we constructed all single mutants of PACAP and
screened them. Deviations of the σ scores of the mutants from
the wild-type (WT) sequence (Δσ) were computed and plotted
on a heat map (Fig. 1H). The large majority of single mutations
reduced or minimized PACAP membrane-permeating proper-
ties. Furthermore, the distribution of Δσ is left-skewed, indi-
cating that the PACAP structure is locally optimized for
membrane-permeating activity (Fig. 1I). Mutations in the
∼10 C-terminal residue domain are especially prone to reduc-
tions in fitness, indicating that membrane activity of PACAP
localizes to this region, whereas GPCR-binding capacity is dis-
tinctly localized to the N terminus (32), highly reminiscent of
mammalian kinocidins (31). The structural compactness of
multipotent PACAP peptides suggests some interpenetration
between these functional domains.
PACAP Induces NGC in Microbial Membranes to Facilitate Potent
Bactericidal and Fungicidal Activity. To dissect the biophysical
mechanisms of PACAP-mediated membrane permeation, we
conducted small-angle X-ray scattering (SAXS) experiments
with model membranes mimicking bacterial and mammalian
cells (Fig. 2 and SI Appendix, Fig. S4). Consistent with machine
learning predictions, PACAP induced NGC in the bacteria-like
PG/PE 20/80 membranes (Fig. 2A) but not in the mammalian-
like PS/PC 20/80 membranes. PACAP induced the formation of
a Pn3m cubic phase with a lattice parameter of a = 28.1 nm and a
corresponding magnitude of NGC = 0.8 × 10−2 nm−2, which is
comparable to the NGC induced by other HDPs. The fact
that PACAP induced NGC comparable to other membrane-
remodeling proteins, including AMPs and cell-penetrating pep-
tides (33), implies one mode of antimicrobial activity is pore
formation (Fig. 2A). To determine whether PACAP is bacteri-
cidal, minimum bactericidal concentration (MBC) plate-killing
assays targeting Staphylococcus aureus, Escherichia coli, or Pseu-
domonas aeruginosa were performed (Fig. 2B). Various concen-
trations of PACAP were incubated with 2 × 105 colony-forming
units (CFU) of bacteria in liquid broth at midlog phase in 96-well
plates and incubated at 37 °C for 1 h. Tenfold serial dilutions were
made with sterile buffer and spotted onto Luria–Bertani (LB) agar
plates and incubated overnight at 37 °C to yield visible colonies.
The MBC (≥3-log reduction of CFUs) of PACAP under physio-
logical salt and buffer compositions ranged between ∼2 and
10 μM, which is comparable to other known HDPs. Since PACAP
is an endogenous peptide and exhibits membrane-permeating ac-
tivity, we studied whether it is cytotoxic to mammalian cells. Lac-
tate dehydrogenase-release assays were conducted with murine
WT bone marrow-derived macrophages (Fig. 2C). PACAP
exhibited a similar cytotoxicity profile to LL37 and was not ap-
preciably toxic relative to control at MBC concentrations. In par-
allel, radial diffusion assays were also performed to measure the
spectrum of antimicrobial activity of PACAP against clinical iso-
lates exhibiting multidrug-resistant (MDR) phenotypes. Fifteen
different strains of bacteria and fungi were tested, under neutral
and acidic pH conditions simulating CNS and bloodstream (pH
7.5) context vs. those encountered in abcesses or phagolysosomal
microenvironments (e.g., pH 5.5; Fig. 2 D–I and SI Appendix, Fig.
S5). Notably, PACAP exhibited potent antimicrobial activity
against MDR S. aureus (SAUSA300), Acinetobacter baumannii
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Fig. 1. PACAP is a GPCR-binding neuropeptide with strong physicochemical homology to human cathelicidin from innate immunity. (A) Screening a neu-
ropeptide database (red) using the support vector machine-based MAPT for sequences with hidden membrane-restructuring activity revealed PACAP (purple)
to be a hypothesized endogenous HDP. LL37 (green) is shown for comparison alongside sequences generated by a Monte Carlo–based directed search of
sequence space (gray). (B) Comparison of the distribution of residue character along the lengths of PACAP and LL37 (blue = cationic, green = hydrophilic,
white = hydrophobic, red = anionic). Helical wheel diagrams of (C) PACAP and (D) LL37 show similar distributions of hydrophobic (yellow) and cationic
residues (teal). Anionic amino acids (red) and polar amino acids (purple) are also shown. (E) PACAP and LL37 exhibit similar lysine-to-arginine ratios and mean
hydrophobicities, which suggests that PACAP (purple) can generate negative Gaussian membrane curvature similar to LL37 (green) and other ɑ-helical AMPs
(gray). (F) Structural alignment of PACAP and LL37 yields an rmsd of 1.184 Å, demonstrating close structural similarity, despite (G) very low sequence ho-
mology. (H and I) An in silico mutational analysis of the entire PACAP sequence demonstrates that PACAP is locally optimized for membrane-remodeling
activity, and that the majority of mutations reduce the microbicidal potential of the peptide.
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(HUMC-1), Candida albicans (CA 36082S) and Salmonella typhi-
murium (ST 5996S) (Fig. 2 D–I). For some strains (e.g.,
SAUSA300), PACAP exhibited pH-dependent antimicrobial ac-
tivity, while for others no statistical differences were observed in
distinct pH conditions (e.g., HUMC-1).
PACAP Is a Multimodal HDP That Kills Bacteria and Fungi via
Synergistic Mechanisms. The preceding experiments demon-
strated that PACAP has properties of an antibacterial and an-
tifungal peptide that can induce NGC to facilitate target cell
membrane disruption. To investigate its mechanisms of action, a
multiparametric flow cytometry system was used to compare
PACAP and other host-defense peptides by single-cell mecha-
nistic fingerprinting (Fig. 3). Results showed that PACAP exerts
antimicrobial activity via multiple mechanisms in an organism-
and context-dependent manner, similar to classical HDPs. For
example, PACAP kills S. aureus primarily via membrane per-
meabilization (PRM) at pH 5.5 but induces greater phosphati-
dylserine accessibility (PSA) and cell death protease (CDP)
levels at pH 7.5; its impact on cellular energetics (ENR) is
common to both conditions (Fig. 3 A–D). Conversely, PACAP
antimicrobial activity against S. typhimurium is mediated less by
ENR or PRM perturbation and more by induction of PSA and
CDP (Fig. 3 E–H). Its antifungal activity against C. albicans is
mediated by both membrane PRM and activation of CDP
(Fig. 3 H–K). Collectively, these data confirm that PACAP
possesses mechanistic signatures consistent with traditional
HDPs that are known to depolarize, permeabilize, and/or induce
regulated cell death pathways in human pathogens.
PACAP Is Strongly and Selectively Induced in the Brain and in Other
Tissues in Response to Infection. As PACAP exhibits potent anti-
bacterial and antifungal activities, we investigated whether its
expression levels in the brain and other tissues are regulated by
bacterial and fungal infection. Murine experimental models of
infection were selected based on clinically relevant parallels to
those in humans, including manifestations in organs such as the
brain, spleen, kidney, skin, and lung. We carried out immuno-
histochemistry of all five tissues in three mouse models of sys-
temic infection (S. aureus, E. coli, or C. albicans). Mice were
hematogenously inoculated with bacteria or fungi and relative
expression levels of PACAP were quantified. Remarkably,
PACAP was potently induced in anatomically relevant tissues
within and beyond the CNS in response to infection (Fig. 4).
Strikingly, in the brain, PACAP was induced up to 40- to 50-fold
in response to S. aureus or C. albicans infection (Fig. 4 A and B
and SI Appendix, Fig. S6). By comparison, PACAP induction as a
result of E. coli infection was substantially more modest. Im-
portantly, gram-staining of brain abscesses demonstrated strong
colocalization of PACAP with S. aureus without infiltration of
immune cells like neutrophils (SI Appendix, Fig. S7). Detailed
pathology revealed vascular access of brain by S. aureus was as-
sociated with a marked up-regulation of perivascular and pa-
renchymal PACAP expression, consistent with a localized
PACAP-mediated response to defend against invasion (SI Ap-
pendix, Fig. S8). We also observed gross preservation of the
parenchymal structure of the tissue despite presence of the mi-
crobial infection 48 h after initial seeding, well within the time-
scale of cellular infiltration. In spleen, PACAP was also
surprisingly strongly induced, where it was markedly up-regulated
∼10- to 30-fold in response to S. aureus or C. albicans infection
(Fig. 4 A and C). As in brain, E. coli induction of PACAP in spleen
was considerably lower. Given that the spleen is a primary lym-
phoid organ important for lymphocyte-mediated and adaptive
immunity, this striking up-regulation in this tissue suggests that
PACAP plays a role in direct innate and adaptive host defense.
This is consistent with the known hardwiring between the CNS
and lymphoid organs via the autonomic nervous system (3). Fi-
nally, we found that PACAP expression levels were induced ∼80-
to 100-fold in the kidney in response to S. aureus and C. albicans.
A B D E
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Fig. 2. PACAP preferentially induces NGC in microbial membranes to facilitate potent bactericidal and fungicidal activity. (A) PACAP recapitulates semi-
selective membrane remodeling activity of HDPs, inducing NGC in the bacterial model membrane PG/PE 20/80, but not in the eukaryotic-like PS/PC 20/80. A
schematic of a transmembrane pore rich in NGC is shown. NGC is present everywhere along the surface highlighted in the dark shaded area spanned by the
principal curvature C1 and C2. (B) PACAP was incubated with bacteria grown to midlog phase (1 × 10
6 CFU/mL). MBC assays were performed on S. aureus
(SA113), E. coli (DH5ɑ), and P. aeruginosa (PA01), demonstrating strong antibacterial activity. (C) LDH-release assays with mouse macrophages demonstrate
that PACAP is nontoxic to eukaryotic cells at bactericidal concentrations. Assays in B and C are representative of three independent experiments. (D–I) Radial
diffusion assays show that PACAP exerts potent antibacterial and antifungal activity against MDR organisms, including MRSA (USA300), A. baumannii (HUMC-1),
and C. albicans (CA 36082S). The diameter of induced clearing d is measured in millimeters. *P < 0.05, **P < 0.01. P values were calculated using a two-tailed
Student’s t test.
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Interestingly, PACAP expression was intensified in the medulla in
response to the fungus C. albicans but more uniformly distributed
vs. S. aureus (Fig. 4 A and D). These findings suggest that PACAP
activity may be influenced by local conditions such as urea or
osmotic tone in these tissue contexts. Expression levels of PACAP
in the skin and the lung were less extensive, although modest in-
duction in the lung parenchyma was observed in response to
E. coli (SI Appendix, Fig. S9).
PACAP Exerts Context-Dependent Antimicrobial Efficacy in the CNS
and Other Tissues. Our experimental in vivo models of infection
identified dramatic PACAP up-regulation in multiple tissues in
response to both bacteria and fungi. To determine whether
PACAP antimicrobial activity varied with biological contexts, we
decided to assess the relative efficacy of PACAP against target
pathogens in vitro under conditions simulating clinically relevant
scenarios, such as abscesses, urinary tract infections, and CNS
infections (Fig. 5). Growth inhibition assays were conducted with
S. aureus, E. coli, and C. albicans in media mimicking the phys-
iological microenvironment of the brain, urine, and abscess. All
three are known to cause septicemia via bloodstream infection.
S. aureus is a common cause of brain abscesses and abscesses in
general, E. coli is the predominant urinary pathogen and can also
cause meningitis, and C. albicans can cause opportunistic infec-
tions in all three contexts. We find remarkable evidence for
context-dependent antimicrobial activity of PACAP. Overall,
PACAP was able to inhibit growth of all three organisms in the
brain, urine, and abscess media to varying degrees, but especially
against S. aureus in the brain, E. coli in the urine, and C. albicans
in the brain, abscess, and urine.
PACAP exhibited the strongest dose-dependent bactericidal
activity against S. aureus in brain-simulating conditions at both
pH 5.5 and 7.5 (Fig. 5A), whereas it had comparatively weaker
activity against S. aureus in media simulating abscess or urine
contexts, although there was still significant activity. This pattern
of results is consistent with the dramatic increase in PACAP
expression observed in the brain upon infection with S. aureus
(Fig. 4). S. aureus is a clinically significant pathogen in the brain,
suggesting that PACAP is evolved to participate in molecular
antimicrobial defense of the CNS while sparing inflammatory
cell infiltration. PACAP activity against E. coli was present in
brain and abscess media at both pH 7.5 and 5.5, with pronounced
anti-E. coli efficacy in urine-simulating medium (Fig. 5B).
PACAP also exhibited potent activity against the C. albicans in
context of brain and abscesses media, and to a lesser degree in
urine medium (Fig. 5C). Taken together, this data profile sug-
gests PACAP is a pathogen-inducible resident antimicrobial
neuropeptide specialized for contextual molecular host defense
of the CNS and other tissues likely to be challenged by cognate,
PACAP-inducible pathogens.
Discussion
Taken together, the present findings elucidate the antimicrobial
properties and spectra, context- and organism-specific responses
in vivo, empiric antimicrobial mechanisms of action and evolution
of PACAP. These findings support the hypothesis that PACAP
provides locally induced antimicrobial defense of the CNS from
invasive bacteria and fungi without evoking immune cell infiltra-
tion and/or parenchymal damage. This strongly conserved neu-
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Mechanism Mechanism Mechanism Mechanism
Mechanism Mechanism Mechanism Mechanism
Fig. 3. PACAP is a multimodal HDP that kills bacteria and fungi via synergistic mechanisms. Mechanistic fingerprinting experiments were conducted using
single-cell flow cytometry. SDS (a membrane detergent), PACAP or comparator HDP LL-37, or kinocidin congeners RP-1 and ɣ-RP-1 were incubated with HDP-
sensitive or HDP-resistant strains of S. aureus (A–D), S. typhimurium (E–H), or C. albicans (I–L) in the presence of specific fluorescent reporters (Materials and
Methods). Six mechanistic parameters were measured in distinct pH conditions mirroring bloodstream (pH 7.5) or abscess/phagolysosomal (pH 5.5) contexts:
forward scatter (FSC; cell size), side scatter (SSC; intracellular refractivity indicative of nucleic acid condensation), cellular membrane energetics (ENR;
transmembrane potential), cell membrane permeability (PRM), PS accessibility (PSA; membrane turnover indicating early-stage regulated cell death), or
activation of CDP (indicative of late-stage regulated cell death) pathways.
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similarities to human cathelicidin LL37, despite low sequence
similarity to known HDPs. PACAP exerts broad-spectrum anti-
bacterial and antifungal efficacy, targeting multiple microbial
pathways including membrane perturbation, disruption of cellular
energetics, and activation of regulated cell-death pathways. Of
special importance, current findings establish that PACAP is po-
tently and selectively induced in the CNS and peripheral tissues
relevant to molecular defense against metastatic seeding in bac-
teremia and fungemia. PACAP responses occurred with minimal
immune cell infiltration or inflammatory damage.
The fact that PACAP is expressed throughout the central, pe-
ripheral, and enteric nervous systems suggests it likely plays a
fundamental role in host defense at the interface of nervous and
immune homeostasis within and beyond the CNS. It is interesting
that PACAP can be expressed at lower levels in immune cells, in
lymphoid organs, in blood matrices, and at immune barriers such
as skin or mucosa. These insights provide strong evidence to
support the hypothesis that PACAP affords rapid and effective
host defense optimized to tissue contexts of infection. Consistent
with this hypothesis, low plasma PACAP levels are observed in
patients with nephrotic syndrome who are at increased risk for
bacterial infection (34). PACAP is also known to be neuro-
protective in mouse models of Alzheimer’s disease (AD) (35),
consistent with hypotheses linking dysfunctions in HDPs or other
immune mediators to AD resulting from latent and/or chronic
CNS infection (36). Recent work has also shown that bacterial and
fungal cryptic infections have been previously linked to AD (37,
38). Collectively, these themes suggest that PACAP is crucial for
CNS antimicrobial host defense and that its deficiency or dysre-
gulation renders hosts at risk for spontaneous or microbe-
catalyzed neurodegeneration.
The established beneficial antiinflammatory and immuno-
modulatory functions of PACAP are consistent with its proposed
role in CNS defense against invasive microbial infection while
preserving CNS and neuronal integrity for cognitive function.
PACAP is a potent suppressor of inflammatory cytokines and
chemokines (3). PACAP has previously been shown to be anti-
inflammatory and neuroprotective in mouse models of multiple
sclerosis (39). This role aligns to modulation of tissue damage
from infection that is not predominantly due to microbe-
mediated toxicity but rather from the off-target inflammatory
response induced by infection (40). Unchecked, such responses
can cause permanent physical and/or cognitive disability due to
neuronal demyelination. Infections that can cause irreversible
neuronal damage include brain abscesses, encephalitis, menin-
gitis, and others. Such infections often evoke hyperinflammatory
responses imposing amplified injurious effects in the confined
space of the CNS. Thus, complementing its direct antimicrobial
role, PACAP has been shown to down-regulate Th1/Th17 po-
larization, which usually induces a neutrophil-predominant im-
mune response (41). In parallel, PACAP also shifts the immune
axis toward a Th2 phenotype, away from cell-mediated immu-
nology and toward molecular and humoral immunity (42). In-




Fig. 4. PACAP is strongly and selectively induced in the brain and other tissues in response to infection. (A) Immunohistochemistry for PACAP in brain, spleen,
and kidney was compared in control (uninfected) and hematogenously-infected mice inoculated with S. aureus (SA), E. coli (EC), or C. albicans (CA). Images
represent at least five independent experiments. PACAP induction was quantified using image processing in ImageJ. Relative change in expression was
calculated vs. control uninfected tissue. All images are shown at 100× magnification. (B) In the brain, PACAP exhibits ∼40- to 50-fold induction in response to
S. aureus and C. albicans infection but not E. coli. (C) In the spleen, PACAP is strongly induced in the presence of all three organisms (∼10- to 25-fold). (D) In the
kidney, PACAP is induced ∼80- to 100-fold in response to infection with S. aureus and C. albicans, similar to brain. In B–D, n = 5 for all conditions, *P < 0.05,
**P < 0.01, ***P < 0.001 relative to control. All other comparisons not significant. P values were calculated using a two-tailed Student’s t test.
6 of 12 | PNAS Lee et al.
https://doi.org/10.1073/pnas.1917623117 PACAP is a pathogen-inducible resident antimicrobial neuropeptide affording rapid and

































(43) and protects against septic shock (44). Thus, our present
findings that PACAP is significantly up-regulated in response to S.
aureus and Candida infection, which are predominantly cleared via
Th17 responses (45) strongly support our hypothesis that PACAP
plays crucial and simultaneous roles to defeat pathogens and limit
any hyperinflammatory responses. This concept is further supported
by the current data demonstrating PACAP to be physicochemically
similar to human cathelicidin LL37. Substantial published evidence
has shown LL37 to confer both immunomodulatory and antiin-
flammatory roles, such as modulation of Toll-like receptors by
binding to pathogen-associated molecular patterns or damage-
associated molecular patterns (28, 46–48).
That PACAP is one of the most conserved peptides throughout
evolution (49) supports our hypothesis that PACAP arose at the
intersection of evolving nervous, immune, and endocrine systems
that emerged in early multicellular organisms and has since
evolved into modern humans. Whether its archetypal role first
emerged as antimicrobial or neurological, it is logical that the
survival advantage afforded by PACAP would have been retained
as an essential and multifunctional effector in higher organisms.
Moreover, the relatively low rate of mutation observed over evo-
lutionary time in PACAP may reflect selective pressure optimi-
zation of multiple integrated constraints to preserve critical
functions, including GPCR-mediated signaling and antimicrobial
as well as neuromodulatory activities. Notably, while the upstream
GPCR-binding domain has been conserved absolutely over the
course of evolution, the C-terminal antimicrobial domain has been
subject to a greater degree of mutational plasticity (11). This may
reflect coevolutionary antimicrobial mechanisms allowing PACAP
to keep pace with rapidly evolving microbial targets. For example,
from a neuroimmunomodulatory perspective, Hydra species pos-
sess rudimentary nervous systems, and a primitive innate immune
system with Toll-like receptors (50). Hence, it stands to reason
that Hydra species express an evolutionarily early PACAP ances-
tor exerting immunomodulatory and antiinfective activities. Also,
a secreted neuropeptide can regulate the microbiome in Hydra
(51), suggesting there are other neuro-AMPs like PACAP that are
yet to be discovered or identified (51–53). Furthermore, prior
investigations have demonstrated that neuropeptides are central
to modulation of neuroinflammation (4) and regulation of the
innate (5) and adaptive (7) immune responses, facilitating ho-
meostatic communications between immune, endocrine, and
nervous systems (6, 8). In support of these concepts, the AMP
NLP-29 regulates neuronal dendrite degeneration in Caeno-
rhabditis elegans (54), of potential relevance to synaptic remodel-
ing during learning. Finally, beyond nervous and lymphoid tissue,
PACAP is highly expressed in gut and skin (55), which comprise
the two largest surfaces for host interaction with microbes (56).
Collectively, the current findings highlight PACAP as a prototype
host-defense neuropeptide with reciprocal antimicrobial and
antineuroinflammatory activity. We hypothesize that PACAP can
serve as a molecular template for design of next-generation anti-
infectives with homeostatic capabilities inherently optimal for
preventing or treating infections within or beyond the CNS.
Finally, the demonstration of a fundamental link between




Fig. 5. PACAP exerts context-dependent antimicrobial efficacy. Growth inhibition assays were conducted in context-dependent media mimicking brain
infections, urinary tract infections, and abscesses (Materials and Methods). For each context, 1 or 10 μg/mL of PACAP simulating low or high expression levels
were incubated with (A) S. aureus, (B) E. coli, or (C) C. albicans at pH 5.5 and pH 7.5. Growth inhibition was measured after incubation at 37 °C. PACAP
inhibited the growth of all organisms in brain-, urine- and abscess-simulating media to varying degrees. PACAP exhibited the strongest bactericidal ability
against S. aureus and C. albicans in brain medium and against E. coli in urine medium. n = 3 for all assay conditions. *P < 0.05, **P < 0.01. All other com-
parisons were not significant. P values were calculated using a two-tailed Student’s t test.
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ancient neuropeptides has potentially broader implications. In
nature, fitness can be enhanced through multiplexed functions
within the same molecule (57). This theme is illustrated by
kinocidins (10, 58–60), which exert direct microbicidal activity,
modulate innate receptors (61), and mediate immune cell che-
motaxis. That molecules can integrate reciprocal immune and
neurological functions raises intriguing possibilities (62, 63). For
example, interestingly, in PACAP knockout models, mice have
mood and psychotic disorders (64), and genetic variants of
PACAP are associated with schizophrenic-like disorders in hu-
mans (65). Moreover, PACAP plasma levels correlate with
symptom severity in posttraumatic stress disorder in humans
(66). For example, GPCR-mediated outcomes such as mood can
be connected to increased host-defense responses or stressors as
occur in relation to microbial challenge or infection (3, 67). In
this light, it is intriguing that the absence of nervousness, anxiety,
and depression-like symptoms in mice (68) is correlated to the
availability of PACAP (64). Importantly, our current findings
support an emerging paradigm in which evolution of immune
and nervous systems is linked (57, 69). The present findings
suggest that microbial infection can lead to a spectrum of GPCR-
activated consequences mediated via neuropeptides that have
multiple functions in host defense and homeostasis. Thus, the
striking rapid and extensive up-regulation of an ancient neuro-
peptide with GPCR-mediated activity in essential tissues (∼50-
fold increase in the infected brain) may impact neuropsychiatric
health and disease, which are emergent properties of the evolved
CNS. Mounting evidence suggests that mental illness, behavioral
stimuli, and sleep abnormalities may also be associated with
consequences of chronic infection (70) beyond disruption of the
microbiome. Conversely, behavioral interventions that modulate
neuropeptide expression could be exploited to alleviate auto-
immunity by suppressing unwanted immune responses (3). In
summary, the specialized need to defend the CNS with resident
neuropeptides rather than immune cells may ultimately reveal
essential intersections between host neurological and immuno-
logical functions, and the microbiome.
Our work demonstrates a clear role for PACAP in context-
dependent host defense in the CNS and other tissues, but the
limitations of the present study should be understood. In order
to more carefully control for experimental variables, our context-
dependent antimicrobial assays were conducted in vitro under
conditions that closely mimic the in vivo physiologic environ-
ment. We did not directly seed microbes into specific tissues
in vivo or administer PACAP as an exogenous therapeutic.
However, our in vivo bacteremia/fungemia model showed how
marked up-regulation of endogenous PACAP production in
tissues correlates with its context-dependent antimicrobial ac-
tivity. Brain infections and abscesses are often the result of he-
matogenous spread rather than direct invasion from the external
environment; thus, our study design more faithfully recapitulated
actual clinical scenarios. We did not explore whether the dra-
matic up-regulation of PACAP resulted from the release of
preformed PACAP or increased transcription of the gene. An-
other aspect that is not addressed experimentally here is the
potential link between PACAP induction during infection and
resulting changes in neuropsychiatric behavior, which would re-
quire behavioral studies in relevant experimental models. While
studies addressing these intriguing hypotheses are beyond the
scope of the current work, they are logical extensions of the
present findings and ongoing in our laboratories.
Materials and Methods
Machine-Learning Screen for Membrane-Active Peptides. A previously devel-
oped machine-learning classifier was used to discover hidden membrane
activity in known neuropeptides. Full details of dataset curation, physico-
chemical descriptor selection, and model training and validation have been
reported previously (9, 26, 33). Briefly, the classifier is based on a linear SVM
that takes as input n = 12 physicochemical descriptors generated from the
peptide sequence and outputs a score σ specifying the distance of the
peptide from an (n − 1) = 11-dimensional hyperplane trained to optimally
separate 243 known α-helical curvature-generating peptides from 243 decoy
peptides. The 12 descriptors provided to the classifier were identified by
principled feature selection as those most discriminatory in classification
accuracy. A large, positive σ score correlates with increased ability to induce
NGC in membranes, whereas a negative σ score indicates a lack of
membrane-disruptive activity. This score can be converted through a
monotonic function into a probability 0 < P(+1) < 1 that the peptide induces
membrane curvature. Large, positive values of σ [P(+1) > 0.95] represent a
high likelihood of membrane activity (ability to generate NGC), and nega-
tive values of σ [P(+1) < 0.50] indicate a low probability of membrane ac-
tivity. Testing of the classifier on a blind balanced test set of 86 peptides
demonstrated 91.9% prediction accuracy, 93.0% specificity, and 90.7%
sensitivity. Experimental validation of computational predictions was carried
out using SAXS. A subset of ⍺-helical test peptides was incubated with model
membranes, and induced NGC was measured. A strong correlation between
the ability to generate NGC in membranes and the distance-to-hyperplane
SVM metric σ was observed. Classification of a single peptide requires ∼0.1 s
of central processing unit time, permitting high-throughput computational
screening for membrane-active peptide discovery and design.
Here, we used the machine-learning-based tool to screen an annotated
neuropeptide database (2) for α-helical neuropeptides with potential anti-
microbial activity in a similar manner to prior work (71). Neuropeptide se-
quences with lengths between 7 and 40 amino acids were considered, in
concordance with the parameters of the training data. Using Python,
physicochemical characteristics were calculated for each neuropeptide se-
quence and σ and P(+1) values were tabulated for each sequence. The top
helical sequences were sorted by descending σ scores. For each peptide, the
minimum homology to known AMPs was calculated (minHomologyAMP)
using the Jukes–Cantor distance metric. The distance was calculated to 301
known helical AMPs pulled from the APD3 database (72).
Sequence Alignment of PACAP Family Sequences and Phylogenetic Reconstruction.
PACAP sequences from multiple organisms were obtained using a search on the
UniProt database. Sequence alignment of PACAP sequences were conducted
usingMUSCLE (https://www.ebi.ac.uk/Tools/msa/muscle/) (73). Sequence similarity
and identity were calculated from the aligned sequences using an online web
tool (www.bioinformatics.org/sms2/ident_sim.html). Phylogenetic trees were
constructed using the PhyML method in SeaView 4.6.3 (74). Sequences were
screened using the machine-learning classifier described above and σ and P(+1)
scores were reported.
Mutational Analysis of PACAP. An in silico exploration of the membrane ac-
tivity fitness landscape of the PACAP sequence was conducted by generating
all 722 unique single mutants (38 × 19) and screening them using the SVM-
based membrane activity classifier (9). The σ values of all single mutants
were quantitatively compared to the WT sequence by the metric Δσ =
σmutant – σWT. An increase in σ upon mutation (Δσ > 0) corresponds to con-
servation of NGC-generating activity, and a decrease in σ upon mutation
(Δσ < 0) predicts a loss of NGC-generating activity. The sign and magnitude
of Δσ for each single mutant is plotted on a heat map and the distribution of
Δσ is quantified.
Comparison of Amino Acid Content in PACAP to That of AMPs. The amino acid
composition of PACAP is compared to the compositions of known AMPs,
including LL37. Previous work demonstrates that a relationship exists be-
tween the lysine-to-arginine ratio and mean hydrophobicity in membrane-
active AMPs and that the relative amounts of these two quantities are major
determinants of membrane remodeling required for topological changes
(75). A set of 301 cationic helical AMP sequences were obtained from the
AMP database as comparators (72). The mean hydrophobicity of a given







where n is the number of amino acids in the peptide and hi is the hydro-
phobicity of the ith amino acid in the peptide using the Eisenberg consensus
hydrophobicity scale (76). The minimum and maximum mean hydrophobic-
ity values within the set of AMP sequences were used to define a range. This
range was then divided into 31 equal bins, into which the peptides were
partitioned. For m peptides in a given bin, we sum over the jth peptide:
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NK + NR ≡
∑mj=1(#  of  K)j
∑mj=1(#  of  K)j +   (#  of  R)j
,
where NK/(NK + NR) is the ratio of the number of lysines to the total number
of lysines plus arginines. For each bin, NK/(NK + NR) vs. mean hydrophobicity
was plotted using Mathematica. PACAP and LL37 were analyzed and plotted
using the same procedure (77).
PACAP/LL37 Sequence and Three-Dimensional Structural Alignment and Protein
Data Bank–Wide Search for Structural Homologs. Initial sequence alignment of
PACAP and LL37 were carried out using the MatchMaker tool in Chimera
(University of California, San Francisco). The Needleman–Wunsch alignment
algorithm was used and the BLOSUM-62 matrix was used for residue simi-
larity. Subsequently, the aligned residue pairs were fitted to generate a
structural alignment. To search for other peptide and protein motifs with
similar secondary structures, a Protein Data Bank–wide protein structural
alignment analysis using DaliLite (78) was conducted on PACAP and LL37.
The results of the analysis were first filtered by their Z-score and rmsd, which
assesses the difference in the spatial arrangement of the amino acids be-
tween the peptide of interest and other proteins. Those with a Z-score
greater than 3.0 and an rmsd value less than 4.0 were kept. The results
were then sorted by percent physicochemical similarity. The functions of
other diverse families of proteins and peptides related in structure were
tabulated.
Host-Defense Peptides. Comparative peptides used in this study are LL37, RP-1,
and ɣ-RP-1. LL37 is a prototypical ⍺-helical human cathelicidin HDP with
previously reported antimicrobial activity (79). The ⍺-helical mimetic peptide
RP-1 is a synthetic 18-amino-acid congener engineered in part from the
microbicidal ⍺-helix domains of the platelet factor 4 family of kinocidins (80).
By comparison, ɣ-RP-1 is an ⍺-helical β−sheet peptide also based upon
platelet factor 4 family of kinocidins. Both RP-1 and ɣ-RP-1 were synthesized,
purified, authenticated by mass spectroscopy, and demonstrated to have
strong antimicrobial activity in vitro and in vivo (81–83).
SAXS Experiments with Model Membranes. Peptides were purchased and
synthesized in high purity (>95% high-performance liquid chromatography)
using solid-phase synthesis (Anaspec). Liposomes were prepared as previously
described elsewhere (9). Briefly, lyophilized DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine), DOPG (1,2-dioleoyl-sn- glycero-3-[phospho-rac-(1-
glycerol)]), and DOPS [1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt)]
were purchased from Avanti Polar Lipids. Stock lipid solutions were dissolved
in chloroform to 20 mg/mL. Mixtures of these lipids were used as models for
bacterial membranes. DOPS and DOPE were mixed at a 1:4 molar ratio (DOPS/
DOPE = 20/80), and DOPG and DOPE were mixed at a 1:4 molar ratio (DOPG/
DOPE = 20/80). Immediately after mixing, chloroform was evaporated under
nitrogen gas, and the lipids were further dried for 24 h under vacuum. Dried
lipids were resuspended and vortexed in 140 mM NaCl + 10 mM Hepes at pH
7.4 to a final concentration of 20 mg/mL. Aqueous lipid solutions were incu-
bated overnight at 37 °C. Liposomes were prepared by sonication of resus-
pended lipids until clear. Monodispersity in size was obtained via extrusion
through a 0.2-μm filter.
Before use, peptides are solubilized in pure nuclease-free water. Lipo-
somes (DOPS/DOPE = 20/80, DOPG/PE 20/80) and peptides were mixed at a
peptide-to-lipid charge ratio (P/L) of 1/2 and equilibrated at room tempera-
ture overnight. Precipitated peptide–lipid complexes were loaded into 1.5-mm
glass quartz capillaries (Mark-tubes; Hilgenberg GmbH) and hermetically sealed.
Samples were incubated at 37 °C and centrifuged down at 6,000 rpm for
20 min before measurement. SAXS experiments were conducted at the
Stanford Synchrotron Radiation Laboratory (BL 4-2) with monochromatic
X-rays of energy 9 keV. Scattered radiation was collected using a Rayonix-
MX225-HE detector (pixel size 73.2 μm). The two-dimensional diffraction
patterns were integrated using the Nika 1.76 package (84) for Igor Pro-6.37
(Wavemetrics) and FIT2D (85). For all samples, multiple measurements of
different samples were taken to ensure mutual consistency. No changes
were observed over multiple experiments and exposures.
SAXS data were analyzed by plotting the integrated scattering intensity
I(q) vs. q using Mathematica. To determine the lipid phases induced in each
sample, the Bragg peak positions were measured, and their ratios were
compared to the permitted reflections for different liquid-crystalline phases
(e.g., lamellar, hexagonal, and cubic). Curvature-generating ability of the
peptides were determined by calculating the lattice parameter a for the
measured cubic phases. Cubic phases observed belonged to the Im3m and
Pn3m space groups. Measured q positions for the Bragg peak reflections
were fitted to the equation qmeasured = 2π√(h2 + k2 + l2)/a, where (hkl) are
the Miller indices (86). The quantity of average induced NGC in the unit cell
was calculated using the equation <k> = 2πχ/A0d2, where χ is the Euler
characteristic and A0 is the surface area per cubic unit cell for each phase.
Parameter values are χ = −4 and A0 = 2.345 for Im3m and χ = −2 and A0 =
1.919 for Pn3m.
Bacterial Killing Assays. Plate killing assays were carried out as previously
described (87). Briefly, S. aureus (SA113), P. aeruginosa (PA01), and E. coli
(DH5⍺) cells from freshly streaked LB broth agar plates were inoculated into
LB and grown overnight at 37 °C in a shaker incubator into the stationary
phase. The next day, a 1/100 dilution was made of the overnight culture into
fresh LB and was incubated at 37 °C for 2 to 3 h to midlog growth phase
(optical density at 600 nm = 0.4 to 0.6). The midlog phase culture was diluted
to 107 CFU/mL in a sterile filtered buffer of 100 mM NaCl + 10 mM Hepes (pH
7.4). We inoculated a 20-μL suspension of each bacteria into 180 μL of buffer
containing various concentrations of PACAP in 96-well plates for a total of
2 × 105 CFU per well (1/2 serial dilutions from 50 μM to 3.125 μM with a
buffer-only control). The 96-well killing plates were sealed with Parafilm and
incubated on microplate shakers at 37 °C for 1 h. Postincubation, 10-fold
serial dilutions were made with sterile buffer. Half of each dilution (100 μL)
was spotted onto LB agar plates and incubated overnight at 37 °C to yield
visible colonies. Colonies were quantified and plotted as a function of an-
timicrobial concentration. All killing assays were done in three replicates
under identical conditions.
Antimicrobial Radial Diffusion Assays. Peptides were assayed for antimicrobial
activity using a well-established radial diffusion method adjusted to pH 7.5
or 5.5 (88). The efficacy of these peptides was evaluated against a panel of
human pathogens, including AMP-susceptible and -resistant isogenic pairs:
S. aureus [ISP479C/ISP479R (89)]; S. typhimurium [MS5996S/MS14028 (83,
90)]; P. aeruginosa (PA01), A. baumanni (19606); and C. albicans [36082S/
36082R (91)]. Bacteria were grown to midlog phase and inoculated at 106
CFU/mL into warm, liquid buffered molecular-grade agarose plates. Peptides
(10 μg) were introduced into wells in the seeded matrix and incubated for
3 h at 37 °C. Nutrient overlay medium was applied, and the agarose plates
were incubated at 37 °C or 30 °C for bacteria or fungi, respectively. After
24 h, zones of inhibition were measured in millimeters. Independent ex-
periments were repeated a minimum of two times.
Cytotoxicity Assays. Cytotoxicity of peptides against WT bone-marrow-derived
macrophages was measured using a lactate dehydrogenase (LDH) release as-
say kit (Promega). Macrophages were grown to confluency in RPMI 1640 +
bovine growth serum + penicillin/streptomycin + L-glutamine (Gibco), washed,
and seeded into 96-well microplates with a final concentration of 105 cells per
well. Peptides were diluted into 140 mM NaCl + 10 mM Hepes (pH 7.4) buffer
and 1:2 serial dilutions were made starting at 100 μM, including a buffer-only
control. Fifty microliters of each peptide at each dilution was transferred into
96-well microplates containing the macrophages and incubated at 3 h in a
37 °C shaker. After incubation, supernatant from the cells were removed and
measured for LDH release. Fifty microliters of supernatant was placed into a
fresh 96-well plate, 50 μL of LDH substrate mix was added, and the plate was
incubated at room temperature for 2 min under foil. Fifty microliters of stop
solution was added, and the plate was centrifuged briefly to remove air
bubbles. The plate absorbance was read at 490 nm and LDH release vs. peptide
concentration was quantified.
Flow Cytometry and Mechanistic Fingerprinting. Mechanisms of PACAP and
comparative host-defense peptide action were assessed as previously de-
scribed (88). PACAP was incubated with a gram-positive (S. aureus), gram-
negative (S. typhimurium), and a fungus (C. albicans). Six-parameter multi-
color flow cytometry was used to analyze four specific mechanisms of HDP
action and two generalized effects associated with the study peptides: 1)
perturbation of cell membrane (CM) energetics (ENR) (e.g., transmembrane
potential), 2) CM permeabilization (PRM), 3) annexin V binding/PSA (nega-
tively charged phospholipids and CM turnover), 4) induction of caspase-like/
metacaspase-like regulated CDP, 5) osmodisruption (forward scatter [FSC]),
and 6) CM invagination/nucleic acid condensation (side scatter [SSC] granu-
larity). The following fluorophores were used with a FACSCalibur instrument
(Becton Dickinson): 3,3-dipentyloxacarbocyanine (DiOC5) (excitation, 484 nm;
emission, 660 nm) (Invitrogen) for ENR, propidium iodide (PI) (excitation,
535 nm; emission, 620 nm) (Sigma) for PRM, annexin V-allophycocyanin con-
jugate (ANX-V) (excitation, 650 nm; emission, 660 nm) (Invitrogen) for ANX,
and CellEvent caspase-3/7 green (C-3/7) (excitation, 502 nm; emission, 530 nm)
(Invitrogen) for CDP. FSC and SSC were measured in parallel. Logarithmic-
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phase organisms were adjusted to 106 CFU/mL in Pipes (pH 7.5) or MES (pH 5.5)
and exposed to 20 μg/mL of each HDP of interest for 1 h at 37 °C. Based on
extensive pilot data, this peptide concentration was used to achieve ∼50%
survival given the high inoculum of bacteria exposed. The HDPs tested in-
cluded PACAP, LL37, and kinocidin congeners RP-1 and ɣ-RP-1. After addition
of the HDP to each organism of interest, a triple-stain mixture containing
DiOC5 (0.5 μM), PI (5.0 μg/mL), and ANX-V (2.5 μL/mL) in 50 mM potassium-
containing MEM (K+ MEM) (without phenol red; Sigma) was added to each
sample following incubation. Samples were stained at room temperature for
15 min before flow cytometry. Parallel samples were incubated with 30 μL of
C-3/7 reagent for 30 min at 37 °C following peptide exposure. After incuba-
tion, 400 mL of phosphate-buffered saline (PBS) was added to remove any
background signal. Sodium dodecyl sulfate (SDS) (10%, wt/vol; Ambion) (a
nonspecific perturbant of ENR and PRM) or buffers alone (K+ MEM or PBS)
were included as controls in each experiment. Fluorescence of a minimum of
10,000 cells was acquired from each sample, and results from a minimum of
two independent studies conducted on different days were used for statistical
analyses. Resulting mechanistic fingerprints (mechanigrams) were visualized
by KyPlot software.
Animal Models of Infection. All animal studies were performed in adherence
to Institutional Animal Care and Use Committee review and approval at the
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical
Center. For bacteremia models, immunocompetent Balb/C mice (22 g) were
acclimated for 2 d prior to infection. S. aureus (strain LAC-USA300), E. coli
(strain 43889), or C. albicans (strain 36082) were used as prototypic gram-
positive bacterium, gram-negative bacterium, and fungal pathogens, respec-
tively. Each of these microbial strains has been well-characterized previously.
Each strain was cultured from virulence-validated master cell banks and grown
to log phase in appropriate media at 37 °C (bacteria) or 30 °C (fungus).
Resulting log-phase cells were harvested, washed, suspended in PBS, sonicated,
quantified by spectrophotometry, and diluted to the desired CFU inoculum in
PBS. Infection was achieved via intravenous tail vein injection using a standard,
nonlethal inoculum of 106 CFU (100 μL PBS). At 48 h postinfection, brain,
kidney, spleen, lung, and skin were excised and processed for quantitative
microbial culture, histology, and immunohistochemistry.
Histology and Immunohistochemistry. Tissue morphology and infection were
assessed by hematoxylin/eosin and gram staining, respectively. PACAP ex-
pression relative to infection was assessed in tissues at the study endpoint as
previously described (92). In brief, tissues were aseptically dissected from
animals, fixed in 10% zinc formalin, and embedded in paraffin. Next, 3-μm
sections were cut, dewaxed, and rehydrated, followed by heat-induced an-
tigen retrieval (Dako). Samples were blocked with dual endogenous enzyme
block (Dako) and 2 to 10% normal serum corresponding to the secondary
antibody. Sections were then incubated with a primary antibody targeting
PACAP (BS-0200R; Bioss), followed by staining with a secondary antibody
conjugated to horseradish peroxidase or biotin (Santa Cruz Biotechnology).
Colorimetric development was achieved by reaction with streptavidin–
horseradish peroxidase (Dako) and 3,3′-diaminobenzidine (DAB; Vector Lab-
oratories), and the samples were counterstained with hematoxylin. Images
were visualized using a Zeiss BX43 microscope with a DP21 digital camera.
Quantification of PACAP Induction from Immunohistochemistry. Immunohis-
tochemistry Images were quantitatively analyzed using ImageJ software
(https://imagej.nih.gov/ij/) (93) as previously described (92). Outcomes were
enumerated as an integral of staining in a given tissue sample compared to
uninfected control. A minimum of five images with identical total areas
were quantified for each study group; areas containing no tissue were
subtracted as background to afford internal control. PACAP expression in-
dices were calculated by comparison to uninfected control values. Data are
presented as mean values ± SDs. Differences in experimental results were
compared by Student’s t test and ANOVA, where appropriate. P values of
P < 0.05 were considered statistically significant. Data were visualized using
GraphPad Prism software.
PACAP Efficacy in Media Simulating Infection Context. In parallel with ex-
perimental murine models of infection in vivo, studies were performed to
assess relative efficacy of PACAP against target pathogens in conditions
simulating cognate physiological contexts in vitro. Organisms were grown to
midlog phase and inoculated at 106 CFU/mL into prewarmed media simu-
lating respective contexts of infection investigated in vivo: 1) brain medium:
RPMI medium (92.5%) containing 5% vol/vol of brain–heart infusion (BHI),
2% vol/vol PBS, and 0.5% mouse serum vol/vol for bacteria (S. aureus or
E. coli) or RPMI medium (67%) containing 30% vol/vol of BHI, 2% vol/vol
PBS, and 0.001% mouse serum vol/vol for C. albicans; 2) abscess medium:
RPMI medium (92.5%) containing 5% vol/vol nutrient broth (NB), 2% vol/vol
PBS, and 0.5% vol/vol mouse serum for bacteria or RPMI medium (84.9%)
containing 15% vol/vol yeast nitrogen broth (YNB with 1% glucose), 2% PBS,
and 0.01% mouse serum for C. albicans; 3) urine medium: HBSS medium
(89.5%) containing 10% vol/vol NB, 38 mM urea, and 6.8 mM sodium chlo-
ride for S. aureus or HBSS medium (94.5%) containing 5% vol/vol NB, 38 mM
urea, and 6.8 mM sodium chloride for E. coli or HBSS medium (84.9%)
containing 15% vol/vol YNB (with 1% glucose), 7.5 mM urea, and 1.4 mM
sodium chloride for C. albicans. PACAP was introduced into media in con-
centrations simulating low (1 μg/mL) vs. high (10 μg/mL) expression, corre-
sponding to findings determined in vivo as induced by distinct organisms in
respective tissues (Fig. 5). Media were incubated at 37 °C and cultured for
survival/nonsurvival at indicated time points. Independent experiments
performed identically were repeated a minimum of three times and results
were analyzed for statistical significance.
Statistical Analyses. Unless otherwise indicated, statistical analysis used an
unpaired Student’s t test. Differences were considered statistically significant
at P < 0.05.
Data Availability. All study data are included in the paper and SI Appendix.
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